Apimeds Pharmaceuticals U... (APUS)
NYSE: APUS
· Real-Time Price · USD
1.85
-0.01 (-0.53%)
At close: Aug 29, 2025, 11:52 AM
Apimeds Pharmaceuticals US Inc Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
Net Income | -3.71M | -1.5M | -1.39M | -1.65M | -1.42M | -1.01M | -777.69K | -285.32K | -175.3K | -139.23K | -74.59K |
Depreciation & Amortization | 232.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 1.7M | n/a | n/a | n/a | -1 | 22.44K | 69.99K | 118.38K | 118.38K | 95.94K | 48.39K |
Other Working Capital | 633.15K | 876.33K | 538.75K | 575.69K | 291.99K | 48.31K | 41.84K | -173.23K | -2.66K | -2.15K | -2.15K |
Other Non-Cash Items | -1.95M | 128.84K | 117.72K | 95.15K | 70.6K | 56.73K | 38.07K | 33K | 24.91K | 16.66K | 8.41K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 289.1K | 876.33K | 538.75K | 575.69K | 291.99K | 48.31K | 41.84K | -173.23K | -2.66K | -2.15K | -2.15K |
Operating Cash Flow | -3.67M | -490.74K | -733.53K | -974.48K | -1.06M | -882.06K | -627.79K | -307.17K | -34.67K | -28.78K | -19.95K |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -13.37K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -13.37K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | 400K | 400K | 150K | 150K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 11.95M | 193.7K | 176.5K | -455K | 568.1K | 468.1K | 477.1K | 1.31M | 291.9K | 291.9K | 282.9K |
Financial Cash Flow | 12.35M | 593.7K | 326.5K | 250K | 1.12M | 1.02M | 1.03M | 1.31M | 291.9K | 291.9K | 282.9K |
Net Cash Flow | 8.67M | 102.96K | -407.03K | -724.48K | 62.87K | 141.04K | 404.31K | 1.01M | 257.23K | 263.12K | 262.94K |
Free Cash Flow | -3.67M | -490.74K | -733.53K | -974.48K | -1.06M | -882.06K | -627.79K | -307.17K | -34.67K | -28.78K | -19.95K |